Diabetes Insipidus
Also known as: DI, Diabetes, Diabetic
Methodology & AI Transparency ⓘ
Diabetes Insipidus Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Diabetes insipidus (DI) causes frequent urination.
- 2 Real-world patient consensus: Diagnostic registry E23.2: Diabetes Insipidus is managed within Diabetes & Glucose (aka DI).
- 3 Typical cash cost range: Primary evaluation for Diabetes Insipidus incorporates fasting insulin/C-peptide quantification [Diabetes Insipidus E23.2] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Diabetes Insipidus: maintaining Fasting Plasma Glucose [Diabetes Insipidus E23.2] within 75 – 95 mg/dL (E23.2).
Ask our AI Specialists anything about Diabetes Insipidus
What Is Diabetes Insipidus?
Diabetes insipidus (DI) causes frequent urination. You become extremely thirsty, so you drink. Then you urinate. This cycle can keep you from sleeping or even make you wet the bed. Your body produces lots of urine that is almost all water. DI is different from diabetes mellitus (DM), which involves insulin problems and high blood sugar. The symptoms can be similar. However, DI is related to how your kidneys handle fluids. It's much less common than DM. Urine and blood tests can show which one you have. Usually, DI is caused by a problem with your pituitary gland or your kidneys. Treatment depends on the cause of the problem. Medicines can often help.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Diabetes Insipidus (code E23.2) is advanced glycation end-product in Diabetes Insipidus (E23.2: microvascular injury), Cross-referenced with NIH MeSH (Diabetes Insipidus), which Type 1 & Type 2 Diabetes clinicians address while surveilling Fasting Plasma Glucose [Diabetes Insipidus E23.2] (75 – 95 mg/dL (E23.2)).
Common Symptoms & Clinical Signs
- • Presentation of Diabetes Insipidus (E23.2): elevated fasting blood in Diabetes Insipidus (E23.2: glucose or post-meal)
- • Secondary Diabetes Insipidus clinical sign: increased thirst [Diabetes Insipidus E23.2]
- • Symptom flares in Diabetes Insipidus correlating with Fasting Plasma Glucose [Diabetes Insipidus E23.2] deviation outside 75 – 95 mg/dL (E23.2)
- • Functional diabetes & glucose impact requiring fasting insulin/C-peptide quantification [Diabetes Insipidus E23.2] evaluation (E23.2)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Diabetes Insipidus Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E23.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Diabetes Insipidus E23.2] | 75 – 95 mg/dL (E23.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Diabetes Insipidus E23.2] | 3.0 – 7.0 uIU/mL (E23.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Diabetes Insipidus (E23.2: mg/dL)) | > 85% (E23.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Diabetes Insipidus
Treatment selection for Diabetes Insipidus depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Diabetes Insipidus)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
Diabetes Insipidus Patient Community & “People Like Me” Threads
Filter Diabetes Insipidus community threads and patient logs by age, biological sex, dosage, and treatment duration.